Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

mycobacteria

  • Open Access
    Insights into the <span class="sc">l</span>,<span class="sc">d</span>-Transpeptidases and <span class="sc">d</span>,<span class="sc">d</span>-Carboxypeptidase of <span class="named-content genus-species" id="named-content-1">Mycobacterium abscessus</span>: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors
    Mechanisms of Resistance
    Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors

    Mycobacterium abscessus is a highly drug-resistant nontuberculous mycobacterium (NTM). Efforts to discover new treatments for M. abscessus infections are accelerating, with a focus on cell wall synthesis proteins (M. abscessus...

    Khalid M. Dousa, Sebastian G. Kurz, Magdalena A. Taracila, Tracey Bonfield, Christopher R. Bethel, Melissa D. Barnes, Suresh Selvaraju, Ayman M. Abdelhamed, Barry N. Kreiswirth, W. Henry Boom, Shannon H. Kasperbauer, Charles L. Daley, Robert A. Bonomo
  • Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant <em>Mycobacterium aurum</em>
    Mechanisms of Resistance
    Fitness Cost and Compensatory Evolution in Levofloxacin-Resistant Mycobacterium aurum

    We isolated spontaneous levofloxacin-resistant strains of Mycobacterium aurum to study the fitness cost and compensatory evolution of fluoroquinolone resistance in mycobacteria. Five of six mutant strains with substantial growth defects showed restored fitness after being serially passaged for 18 growth cycles, along with increased cellular ATP level. Whole-genome...

    Rui Pi, Qingyun Liu, Howard E. Takiff, Qian Gao
  • Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug
    Mechanisms of Resistance
    Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug

    Isoniazid (INH) is a cornerstone of antitubercular therapy. Mycobacterium tuberculosis complex bacteria are the only mycobacteria sensitive to clinically relevant concentrations of INH. All other mycobacteria, including M. marinum and M...

    Tali H. Reingewertz, Tom Meyer, Fiona McIntosh, Jaryd Sullivan, Michal Meir, Yung-Fu Chang, Marcel A. Behr, Daniel Barkan
  • <em>In Vitro</em> Susceptibility Testing of GSK656 against <em>Mycobacterium</em> Species
    Susceptibility
    In Vitro Susceptibility Testing of GSK656 against Mycobacterium Species

    In this study, we aimed to assess the in vitro susceptibility to GSK656 among multiple mycobacterial species and to investigate the correlation between leucyl-tRNA synthetase (LeuRS) sequence variations and in vitro susceptibility to GSK656 among mycobacterial species. A total of 187 mycobacterial isolates, comprising 105 Mycobacterium tuberculosis...

    Wenzhu Dong, Shanshan Li, Shu’an Wen, Wei Jing, Jin Shi, Yifeng Ma, Fengmin Huo, Fei Gao, Yu Pang, Jie Lu
  • Antimicrobial Susceptibility of Clinical and Environmental <span class="named-content genus-species" id="named-content-1">Mycobacterium chimaera</span> Isolates
    Susceptibility
    Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates

    Mycobacterium chimaera is a slow-growing nontuberculous Mycobacterium species belonging to the Mycobacterium avium complex (MAC). It has been identified globally as the cause of a large outbreak of cardiovascular infections following open heart surgery, but it can also cause respiratory...

    Simone Mok, Margaret M. Hannan, Lars Nölke, Patrick Stapleton, Niamh O’Sullivan, Philip Murphy, Anne Marie McLaughlin, Eleanor McNamara, Margaret M. Fitzgibbon, Thomas R. Rogers
  • Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in <em>Mycobacterium abscessus</em>
    Susceptibility
    Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

    Nontuberculous mycobacteria (NTM) are highly drug-resistant, opportunistic pathogens that can cause pulmonary disease. The outcomes of the currently recommended treatment regimens are poor, especially for Mycobacterium abscessus. New or repurposed drugs are direly needed. Auranofin, a gold-based antirheumatic agent, was investigated for...

    Mike Marvin Ruth, Mara van Rossum, Valerie A. C. M. Koeken, Lian J. Pennings, Elin M. Svensson, Carolien Ruesen, Edmee C. Bowles, Heiman F. L. Wertheim, Wouter Hoefsloot, Jakko van Ingen
  • Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in <em>Mycobacterium tuberculosis</em>
    Editor's Pick Mechanisms of Action: Physiological Effects
    Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis

    There is an urgent need for novel therapeutics to treat Mycobacterium tuberculosis infections. Genetic strategies for validating novel targets are available, yet their time-consuming nature limits their utility. Here, using MmpL3 as a model target, we report on the application of mycobacterial CRISPR interference for the rapid validation of target essentiality and...

    Matthew B. McNeil, Gregory M. Cook
  • A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria
    Susceptibility
    A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria

    The development of antibiotic-resistant bacteria is a worldwide health-related emergency that calls for new tools to study the bacterial metabolism and to obtain fast diagnoses. Indeed, the conventional analysis time scale is too long and affects our ability to fight infections.

    A. Mustazzolu, L. Venturelli, S. Dinarelli, K. Brown, R. A. Floto, G. Dietler, L. Fattorini, S. Kasas, M. Girasole, G. Longo
  • <em>In Vitro</em> Activity of PBTZ169 against Multiple <span class="named-content genus-species" id="named-content-1">Mycobacterium</span> Species
    Mechanisms of Resistance
    In Vitro Activity of PBTZ169 against Multiple Mycobacterium Species

    In this study, we demonstrate that PBTZ169 exhibits significant differences in in vitro activity against multiple Mycobacterium species. The amino acid polymorphism at codon 387 of decaprenylphosphoryl-beta-d-ribose oxidase (DprE1) can be used as a surrogate marker for in vitro susceptibility to PBTZ169 in mycobacteria.

    ...
    Jin Shi, Jie Lu, Shu'an Wen, Zhaojing Zong, Fengmin Huo, Jingjing Luo, Qian Liang, Yunxu Li, Hairong Huang, Yu Pang
  • Growing Knowledge about <span class="named-content genus-species" id="named-content-1">Mycobacterium simiae</span> from Two Recent Studies
    Letter to the Editor
    Growing Knowledge about Mycobacterium simiae from Two Recent Studies
    Amal Hamieh, Ralph Tayyar, Souha Kanj

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596